WakeTherapy: Out-patient Wake Therapy, Light Therapy and Sleep Phase Advance for Depression

Sponsor
New York State Psychiatric Institute (Other)
Overall Status
Completed
CT.gov ID
NCT02750631
Collaborator
(none)
30
1
1
39
0.8

Study Details

Study Description

Brief Summary

Depressed patients miss a night of sleep (Wake Night), then sleep at predetermined times ending at their desired sleep time. Beginning the morning following their Wake Night, patients sit in front of a bright light, continuing morning bright light and specified sleep time for six weeks with weekly visits measuring depressive symptoms.

Condition or Disease Intervention/Treatment Phase
  • Other: Triple Therapy
N/A

Detailed Description

Nonpsychotic, nonbipolar, physically healthy depressed patients keep sleep, mood and energy logs for a week, complete the Morningness-Eveningness Questionnaire (measuring "morningness" and "eveningness") and determine the time patients want to sleep. Patients then miss a night of sleep and subsequently are allowed later and later sleep times until patients are sleeping at their desired time. Beginning the morning following their Wake Night, patients sit in front of bright lights at their intended wake-up time for the next six weeks and once their allowed sleep time is their intended sleep time, patients also continue to only be allowed to sleep between those times (e.g., 11 p.m. to 7 a.m.). Daily sleep, energy and mood logs and activity monitoring are maintained throughout with weekly clinician ratings. In additional, daily telephone check ins occur during the first week following the Wake Night both to be sure the patient is following the protocol and to obtain symptom ratings. Saliva to be measured for melatonin is collected prior to and following sleep adjustment.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
All patients receive Chronotherapy, which consists of a night of no sleep ("Wake Therapy") followed by bright lights at their desired sleep time and two nights of Sleep Phase Advance (i.e., sleeping 6 hours earlier than desired for 1 night and 3 hours earlier for the next night, then desired sleep time).All patients receive Chronotherapy, which consists of a night of no sleep ("Wake Therapy") followed by bright lights at their desired sleep time and two nights of Sleep Phase Advance (i.e., sleeping 6 hours earlier than desired for 1 night and 3 hours earlier for the next night, then desired sleep time).
Masking:
None (Open Label)
Masking Description:
All patients and staff know what the treatment is.
Primary Purpose:
Treatment
Official Title:
Out-patient Wake Therapy, Light Therapy and Sleep Phase Advance for Depression
Study Start Date :
Apr 1, 2014
Actual Primary Completion Date :
Jul 1, 2017
Actual Study Completion Date :
Jul 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Triple Therapy

Combined Wake Therapy (one night of missed sleep), early morning bright light and sleep phase advance

Other: Triple Therapy
The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
Other Names:
  • Chronotherapeutics
  • Outcome Measures

    Primary Outcome Measures

    1. 17-item Hamilton Rating Scale for Depression [1 week]

      The Hamilton Rating Scale for Depression is a standard clinician scored rating of depressed mood and the symptoms commonly associated with clinical depression

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • major depressive disorder or persistent depressive disorder or unspecified depressive disorder

    • physically healthy

    • patients over age 60 need primary care physician's approval, electrocardiogram and Mini Mental Status Examination

    Exclusion Criteria:
    • medically unstable condition

    • bipolar disorder

    • current (past six months) substance use disorder

    • significant suicide risk

    • need for hospitalization

    • history of psychosis

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 New York State Psychiatric Institute New York New York United States 10032

    Sponsors and Collaborators

    • New York State Psychiatric Institute

    Investigators

    • Principal Investigator: Jonathan W Stewart, M.D., New York State Psychiatric Institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    New York State Psychiatric Institute
    ClinicalTrials.gov Identifier:
    NCT02750631
    Other Study ID Numbers:
    • 6938
    First Posted:
    Apr 25, 2016
    Last Update Posted:
    Aug 29, 2017
    Last Verified:
    Aug 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by New York State Psychiatric Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 29, 2017